Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA: 688506)

Sichuan Biokin Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4,976	403.96	1,005	154.22	47.2	246.78
Trading Asset Securities	-	-	-	-	197.54	-
Cash & Short-Term Investments	4,976	403.96	1,005	154.22	244.74	246.78
Cash Growth	1101.74%	-59.79%	551.49%	-36.99%	-0.83%	252.75%
Accounts Receivable	93.5	137.85	267.92	134.95	226.49	309.08
Other Receivables	23.72	3.9	5.14	2.95	0.64	0.07
Receivables	117.22	141.75	273.06	137.9	227.13	309.16
Inventory	164.88	140.91	101.33	82.33	65.77	77.29
Other Current Assets	882.93	89.2	47.22	49.36	33.21	25.78
Total Current Assets	6,142	775.82	1,426	423.81	570.85	659
Property, Plant & Equipment	546.67	534.79	420.26	404.98	380.91	347.96
Other Intangible Assets	26.94	28	29.53	31.16	32.88	34.46
Long-Term Deferred Tax Assets	222.08	76.18	83.23	65.8	48.2	36.27
Long-Term Deferred Charges	3.8	1.82	1.79	1.16	0.67	0.94
Other Long-Term Assets	19.14	8.5	30.28	24.54	8.47	12.06
Total Assets	6,960	1,425	1,991	951.46	1,042	1,091
Accounts Payable	387.11	160.17	128.85	45.96	67.96	56.63
Accrued Expenses	53.6	257.88	244.81	139.81	204.43	244.42
Short-Term Debt	650.71	275.12	155.13	161.23	150.21	195.04
Current Portion of Long-Term Debt	271.68	174.37	30.47	0.02	-	-
Current Portion of Leases	-	46.13	68.82	24.23	-	-
Current Income Taxes Payable	222.88	0.01	4.96	1.54	10.31	7.37
Current Unearned Revenue	350.37	8.67	17.42	10.78	18.1	-
Other Current Liabilities	131.98	131.48	86.74	87.75	81.44	110.65
Total Current Liabilities	2,068	1,054	737.2	471.32	532.45	614.12
Long-Term Debt	613.83	183.92	239.96	50	-	-
Long-Term Leases	14.29	8.65	52.95	51.42	-	-
Long-Term Unearned Revenue	11.59	15.63	13.29	31.04	37.24	28.84
Long-Term Deferred Tax Liabilities	-	-	0.08	-	0.08	-
Other Long-Term Liabilities	10.23	11.19	14.05	15.81	20.14	19.51
Total Liabilities	2,718	1,273	1,058	619.61	589.91	662.46
Common Stock	401	401	401	360.9	360.9	115.94
Additional Paid-In Capital	867.76	858.69	858.55	14.17	14.07	253.11
Retained Earnings	2,956	-1,109	-328.45	-45.98	74.01	44.01
Comprehensive Income & Other	16.72	1.13	2.79	2.76	3.1	5.12
Total Common Equity	4,242	151.87	933.89	331.85	452.08	418.18
Minority Interest	-	-	-	-	-	10.04
Shareholders' Equity	4,242	151.87	933.89	331.85	452.08	428.22
Total Liabilities & Equity	6,960	1,425	1,991	951.46	1,042	1,091
Total Debt	1,550	688.19	547.33	286.91	150.21	195.04
Net Cash (Debt)	3,426	-284.23	457.41	-132.69	94.53	51.74
Net Cash Growth	4113.92%	-	-	-	82.72%	-
Net Cash Per Share	8.58	-0.71	1.26	-0.37	0.27	0.13
Filing Date Shares Outstanding	401	401	401	360.9	344.56	386.54
Total Common Shares Outstanding	401	401	401	360.9	344.56	386.54
Working Capital	4,073	-278.01	689.14	-47.51	38.4	44.88
Book Value Per Share	10.58	0.38	2.33	0.92	1.31	1.08
Tangible Book Value	4,215	123.88	904.36	300.69	419.2	383.72
Tangible Book Value Per Share	10.51	0.31	2.26	0.83	1.22	0.99
Buildings	-	304.56	302.23	300.82	252.7	250.33
Machinery	-	554.25	439.83	419.75	363.73	343.12
Construction In Progress	-	81.37	67.21	18.18	76.71	21.32

Source: S&P Capital IQ. Standard template. Financial Sources.